Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors

被引:0
|
作者
Fatma Ilknur Cinar
Muhammet Cinar
Sedat Yilmaz
Ismail Simsek
Hakan Erdem
Salih Pay
机构
[1] Gulhane Military Medical Academy,School of Nursing
[2] Gulhane Military Medical Academy,Division of Rheumatology, School of Medicine
来源
关键词
Ankylosing spondylitis; Anti-TNF-α therapy; Patients’ perceptions;
D O I
暂无
中图分类号
学科分类号
摘要
The risk of infections and malignancies is the major area of concern with anti-tumor necrosis factor (anti-TNF) agents. The aim of this study was to investigate patients’ views about their treatments and the factors that influence patients’ treatment decisions concerning the use of anti-TNF-α drugs. This descriptive study was conducted in a single rheumatology unit. Patients using anti-TNF-α drugs for at least 3 months were included. Patients’ thoughts and perceptions about their treatment were evaluated using a questionnaire. A total of 101 (94.1 % male) patients were recruited. The patients described their feelings as hopeful, worried, happy, scared, desperate, and hopeless, with the order decreasing beginning with the first. Hope for healing and an expectation of increased quality of life were the most significant determinants for acceptance of treatment. After the drug information was given, patients described their feelings as follows: increase in anxiety, psychologically wearisome, and worrying about their condition worsening in the future. After anti-TNF-α treatment, patients described their experience as follows: “the most effective medicine that I have ever used,” “it saved my life,” “control procedures that were carried out before the treatment and once every 3 months after the treatment were essential,” “I feel myself safe with these controls,” and “I advised other people.” This study, to our knowledge, is the first to evaluate the attitudes of patients concerning anti-TNF-α drugs from the stage of informed consent to the post-experience stage. We found that standard consent forms caused an increase in the level of anxiety among new users of anti-TNF-α drugs, although the aim was the exact opposite. The reasons for acceptance were the hope for healing, reliance on physicians, and advice of other patients. Most patients accepted follow-up control procedures, which aimed to diagnose adverse effects early.
引用
收藏
页码:979 / 986
页数:7
相关论文
共 50 条
  • [41] Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors
    Essers, Ivette
    van Tubergen, Astrid
    Heldmann, Frank
    Baraliakos, Xenofon
    Braun, Juergen
    Kiltz, Uta
    Boonen, Annelies
    RMD OPEN, 2015, 1 (01):
  • [42] LONG-TERM EFFICACY AND SAFETY OF TNF INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A SINGLE CENTRE EXPERIENCE
    Bahtiyar, Toz
    Murat, Erdugan
    Emin, Oguz
    Bahar, Artim-Esen
    Burak, Erer
    Sevil, Kamali
    Ahmet, Gul
    Murat, Inanc
    Lale, Ocal
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 45 - 45
  • [43] A possible way to overcome secondary anti TNF inhibitors inefficiency in patients with ankylosing spondylitis: clinical case
    Lapshina, S.
    Protopopov, M.
    Myasoutova, L.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 124 - 125
  • [44] COMPARATIVE DRUG SURVIVAL OF TNF INHIBITORS AND SECUKINUMAB IN BIOLOGIC NAIVE PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Cheila, M.
    Douglas, K.
    Koutsianas, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 723 - 724
  • [45] Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors
    Movassaghi, Shafieh
    SeyedAlinaghi, SeyedAhmad
    Rostamian, Abdolrahman
    Najafizadeh, Seyed Reza
    Nezhadseifi, Elham
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (06)
  • [46] Determinants of 12-Months Persistence in Ankylosing Spondylitis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 514 - 515
  • [47] Effect of TNF inhibitors on BMD in patients with ankylosing spondylitis-a systematic review and meta-analysis
    Haroon, Nisha Nigil
    Srighanthan, Jeevitha
    Cheung, Angela M.
    Inman, Robert. D.
    Al Ghanim, Nayef
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [48] IMPACT OF GENDER ON PATIENT PROFILE AND TREATMENT RESPONSE IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH TNF-A INHIBITORS
    Milic, B.
    Ilic, T.
    Popovic, M.
    Erdeljan, B.
    Jankovic, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1617 - 1617
  • [49] Retention Rate of TNF Inhibitors ( TNFi) in Ankylosing Spondylitis (AS) Patients from the Rhumadata Clinical Database and Registry
    Popescu, Mihaela
    Choquette, Denis
    Coupal, Louis
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1187 - 1187
  • [50] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Axel Svedbom
    Johan Dalén
    Moa Ivergård
    Rebekah H. Borse
    Christopher M. Black
    Karin Luttropp
    Sumesh Kachroo
    The European Journal of Health Economics, 2020, 21 : 45 - 54